AR013094A1 - Compuestos de urea n-sustituida,composicion farmaceutica y uso de dichos compuestos para preparar medicamentos - Google Patents

Compuestos de urea n-sustituida,composicion farmaceutica y uso de dichos compuestos para preparar medicamentos

Info

Publication number
AR013094A1
AR013094A1 ARP980102858A ARP980102858A AR013094A1 AR 013094 A1 AR013094 A1 AR 013094A1 AR P980102858 A ARP980102858 A AR P980102858A AR P980102858 A ARP980102858 A AR P980102858A AR 013094 A1 AR013094 A1 AR 013094A1
Authority
AR
Argentina
Prior art keywords
hydrogen
compounds
alkyl
independently selected
represent
Prior art date
Application number
ARP980102858A
Other languages
English (en)
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR013094A1 publication Critical patent/AR013094A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP980102858A 1997-06-17 1998-06-16 Compuestos de urea n-sustituida,composicion farmaceutica y uso de dichos compuestos para preparar medicamentos AR013094A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87704997A 1997-06-17 1997-06-17

Publications (1)

Publication Number Publication Date
AR013094A1 true AR013094A1 (es) 2000-12-13

Family

ID=25369144

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102858A AR013094A1 (es) 1997-06-17 1998-06-16 Compuestos de urea n-sustituida,composicion farmaceutica y uso de dichos compuestos para preparar medicamentos

Country Status (14)

Country Link
EP (1) EP0989979A1 (https=)
JP (1) JP2002506444A (https=)
KR (1) KR20010013881A (https=)
CN (1) CN1267291A (https=)
AR (1) AR013094A1 (https=)
AU (1) AU8253598A (https=)
CA (1) CA2293706C (https=)
CO (1) CO4940458A1 (https=)
HU (1) HUP0002954A3 (https=)
IL (1) IL133389A0 (https=)
NZ (1) NZ501571A (https=)
PE (1) PE82799A1 (https=)
WO (1) WO1998057948A1 (https=)
ZA (1) ZA985205B (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
CA2424797C (en) 2000-10-05 2009-12-29 George Q. Daley Methods of inducing cancer cell death and tumor regression
JP4769082B2 (ja) * 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
JP6473133B2 (ja) * 2013-03-15 2019-02-20 アラクセス ファーマ エルエルシー Krasg12cの共有結合性阻害剤
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Kras g12c之抑制劑
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
ES2826443T3 (es) 2014-09-25 2021-05-18 Araxes Pharma Llc Inhibidores de proteínas mutantes KRAS G12C
JP2018513853A (ja) 2015-04-10 2018-05-31 アラクセス ファーマ エルエルシー 置換キナゾリン化合物およびその使用方法
JP6789239B2 (ja) 2015-04-15 2020-11-25 アラクセス ファーマ エルエルシー Krasの縮合三環系インヒビターおよびその使用の方法
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356353A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058807A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
JP2018533939A (ja) 2015-10-19 2018-11-22 アラクセス ファーマ エルエルシー Rasの阻害剤をスクリーニングするための方法
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
CN111960990A (zh) * 2020-07-23 2020-11-20 宿迁联盛科技股份有限公司 一种助剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
SK86198A3 (en) * 1995-12-22 1999-02-11 Schering Corp Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
NZ334437A (en) * 1996-09-13 2000-09-29 Schering Corp Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase
SK33699A3 (en) * 1996-09-13 2000-03-13 Schering Corp Tricyclic compounds useful for inhibition of farnesyl protein transferase

Also Published As

Publication number Publication date
CA2293706A1 (en) 1998-12-23
JP2002506444A (ja) 2002-02-26
EP0989979A1 (en) 2000-04-05
WO1998057948A1 (en) 1998-12-23
HUP0002954A2 (hu) 2001-06-28
HUP0002954A3 (en) 2002-11-28
NZ501571A (en) 2002-02-01
CA2293706C (en) 2008-11-18
KR20010013881A (ko) 2001-02-26
IL133389A0 (en) 2001-04-30
ZA985205B (en) 1998-12-15
CN1267291A (zh) 2000-09-20
AU8253598A (en) 1999-01-04
PE82799A1 (es) 1999-08-26
CO4940458A1 (es) 2000-07-24

Similar Documents

Publication Publication Date Title
AR013094A1 (es) Compuestos de urea n-sustituida,composicion farmaceutica y uso de dichos compuestos para preparar medicamentos
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
DK0650476T3 (da) Perifert, vasodilaterende middel, der indeholder N-acylerede 4-aminopiperidinderivater som aktive bestanddele
TR199902203T2 (xx) Fernesil transferaz engelleyici, N-veya C-ba�lant�l� imidazoller ile ikame edilmi� 1,8-anele kinolinon t�revleri.
DK365184D0 (da) 1,8-naphthyridinderivater eller estre eller salte deraf, deres fremstilling og anvendelse som farmaceutika
CO4650042A1 (es) Derivados de 6-fenilpiridil-2-amina
AR003936A1 (es) Compuestos triciclicos y composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento util para inhibir elcrecimiento anormal de celulas.
PE20011001A1 (es) Compuestos heterociclicos como inhibidores del intercambio de sodio/protones
ES2195034T3 (es) Inhibidor de metaloproteinasas, composicion farmaceutica que contiene este inhibidor y su utilizacion farmaceutica, y procedimientos que sirven para su preparacion.
ES2196772T3 (es) Compuestos amino ciclicos.
AR025276A1 (es) El uso de un compuesto que es un derivado de 2-amino-1,3-tiazol, un compuesto que es un derivado de 2-amino-1,3-tiazol, un procedimiento para producirlo y una composicion farmaceutica que lo comprende
CO5570660A2 (es) Indazolilpirrolotriazinas c-6 modificadas
ES2150577T3 (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
TR200100439T2 (tr) 1H-İmidazopiridin türevleri
FR2599740B1 (fr) Derives de benzo(b)thiophene de benzo(b)furannecarboxamides, leurs procedes de preparation et les medicaments les contenant
BR9811557A (pt) Derivados do 2-)4-aril ou heteroaril-piperazin-1-ilmetil)-1h-indol
DK39286D0 (da) Imidazolderivater, fremgangsmaade til fremstilling heraf og farmaceutiske praeparater indeholdende disse derivater
AR019674A1 (es) Compuestos antitromboticos y composiciones farmaceuticas que los contienen
ES2094146T3 (es) Derivados de la piridazina, procedimiento de preparacion y composiciones farmaceuticas que los contienen.
PE20040750A1 (es) Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3
ES2090024T3 (es) Compuestos de cefemo y procedimientos para su preparacion.
AR041218A1 (es) Derivados de indolilo, un proceso para su preparacion, composicion farmaceutica que lo contiene y uso del compuesto para preparar un medicamento
AR027578A1 (es) Derivados de indano
MX9603998A (es) Agonista receptor de 5-ht3, derivado de tiazol novedoso e intermediario del mismo.
ES2160726T3 (es) Derivados de piperazin-2,5-diona como moduladores de resistencia a multiples farmacos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure